苯并五元杂环化合物抑制SHP2生物活性研究
Biological Evaluation of Benzo[c]heterocyclic Compounds against SHP2
摘要: 为拓展含苯并噻二唑结构单元的SHP抑制剂的化学空间，我们将苯并噻二唑结构单元转化为苯并噻唑、苯并咪唑、吲哚等结构单元，设计并合成了8个苯并五元杂环化合物。活性测试结果表明，部分化合物对SHP2显示了一定强度的抑制活性。其中化合物14 (IC50 = 26.22 μM)对SHP2显示了中等强度的抑制活性。
Abstract: To explore the chemical space of SHP2 inhibitors by changing Benzo[c][1,2,5]thiadiazole moiety in-to Benzo[c]heterocycle moiety, a series of Benzo[c]heterocyclic compounds have been designed, synthesized and evaluated their biological activities against SHP2. Among them, compound 14 dis-played moderate inhibitory activity with IC50 of 26.22 μM against SHP2.
文章引用：冯勃, 陈晓禹, RajendranSatheeshkumar, 王文龙. 苯并五元杂环化合物抑制SHP2生物活性研究[J]. 药物化学, 2020, 8(3): 79-83. https://doi.org/10.12677/HJMCe.2020.83009

参考文献

[1] Zhang, J., Zhang, F. and Niu, R. (2015) Functions of Shp2 in Cancer. Journal of Cellular and Molecular Medicine, 78, 2075-2083. [Google Scholar] [CrossRef] [PubMed]
[2] Frankson, R., Yu, Z.H., Bai, Y., Li, Q., Zhang, R.Y., et al. (2017) Therapeutic Targeting of Oncogenic Tyrosine Phosphatases. Cancer Research, 7, 5701-5705. [Google Scholar] [CrossRef] 
[3] Chen, Y.N., LaMarche, M.J., Chan, H.M., Fekkes, P., Carcia-Fortanet, J., et al. (2016) Allosteric Inhibition of SHP2 Phosphatase Inhibits Cancers Driven by Receptor Tyro-sine Kinases. Nature, 535, 148-152. [Google Scholar] [CrossRef] [PubMed]
[4] Butterworth, S., Overduin, M. and Barr, A.J. (2014) Targeting Protein Tyrosine Phosphatase SHP2 for Therapeutic Intervention. Future Medicinal Chemistry, 6, 1423-1437. [Google Scholar] [CrossRef] [PubMed]
[5] Sarver, P., Acker, M., Bagdanoff, J.T., Chen, Z., et al. (2019) 6-Amino-3-Methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors. Journal of Medicinal Chemistry, 62, 1793-1802. [Google Scholar] [CrossRef] [PubMed]
[6] Wu, X., Xu, G., Li, X., Xu, W., et al. (2019) Small Molecule Inhibitor That Stabilizes the Autoinhibited Conformation of the Oncogenic Tyrosine Phosphatase SHP2. Journal of Me-dicinal Chemistry, 62, 1125-1137. [Google Scholar] [CrossRef] [PubMed]
[7] Pádua, R.A.P., Sun, Y., Marko, I., Pitsawong, W., et al. (2018) Mechanism of Activating Mutations and Allosteric Drug Inhibition of the Phosphatase SHP2. Nature Communi-cation, 9, 4507. [Google Scholar] [CrossRef] [PubMed]
[8] Xie, J., Si, X., Gu, S., Wang, M., et al. (2017) Allosteric Inhib-itors of SHP2 with Therapeutic Potential for Cancer Treatment. Journal of Medicinal Chemistry, 60, 10205-10219. [Google Scholar] [CrossRef] [PubMed]
[9] Wang, R.R., Liu, W.S., Zhou, L., Ma, Y. and Wang, R.L. (2019) Probing the Acting Mode and Advantages of RMC-4550 as an Src-Homology 2 Domain-Containing Protein Ty-rosine Phosphatase (SHP2) Inhibitor at Molecular Level through Molecular Docking and Molecular Dynamics. Journal of Biomolecular Structure and Dynamics, 38, 1-14. [Google Scholar] [CrossRef] [PubMed]
[10] Wang, W.-L., Chen, X.-Y., Gao, Y., Gao, L.-X., et al. (2017) Benzo[c][1,2,5]thiadiazole Derivatives: A New Class of Potent Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) Inhibitors. Bioorganic & Medicinal Chemistry Letters, 27, 5154-5157. [Google Scholar] [CrossRef] [PubMed]